Table 2.
Course characteristics and infection outcomes (N = 127)
| All (N = 127) | Intensive treatment (N = 101) | APL-specific treatment (N = 99) | |
|---|---|---|---|
|
Course characteristics |
|
|
|
| Number with neutropenia (ANC <0.5 × 109) at start of course (%) |
27 (21.3) |
27 (26.7) |
21 (21.2) |
| Median days with neutropenia1(IQR) |
7.5 (0.0, 19.0) |
11.0 (0.0, 20.0) |
3.0 (0.0, 18.0) |
| Median days receiving systemic corticosteroids (IQR) |
0.0 (0.0, 5.0) |
0.0 (0.0, 6.0) |
0.0 (0.0, 3.0) |
| Median corticosteroid dose1 (IQR) |
0.0 (0.0, 29.7) |
0.0 (0.0, 38.4) |
0.0 (0.0, 5.7) |
|
Supportive care |
|
|
|
| Co-trimoxazole prophylaxis (%) |
89 (70.1) |
71 (70.3) |
77 (77.8) |
| Other antibacterial prophylaxis (%) |
0 |
0 |
0 |
| Fluconazole prophylaxis (%) |
30 (23.6) |
27 (26.7) |
18 (18.2) |
|
Infection outcomes2 |
|
|
|
| Sterile site microbiologically documented infection (%) |
15 (11.8) |
14 (13.9) |
9 (9.1) |
| Sterile site Gram-positive (%) |
12 (9.5) |
11 (10.9) |
7 (7.1) |
| Sterile site Gram-negative (%) |
4 (3.2) |
4 (4.0) |
2 (2.0) |
| Sterile site fungus (%) |
2 (1.6) |
2 (2.0) |
2 (2.0) |
| Bacteremia (%) |
11 (8.7) |
10 (9.9) |
7 (7.1) |
| Clinically documented infection (%) |
30 (23.6) |
24 (23.8) |
26 (26.3) |
| Sepsis |
8 (6.3) |
7 (6.9) |
8 (8.1) |
| Infectious death | 1 (0.8) | 1 (1.0) | 1 (1.0) |
Abbreviations: ANC absolute neutrophil count, IQR interquartile range; 1 Presented as mg/m2 of dexamethasone equivalents; 2Infection outcomes represent at least one event per course; number of specific infections do not add to the total as 3 courses had multiple infection types.